Safety and efficacy of the mesenchymal stromal cells therapy for the accelerates engraftment in the hematopoietic stem cell transplantation

Safety and efficacy of the mesenchymal stromal cells therapy for the accelerates engraftment in the hematopoietic stem cell transplantation - Safety and efficacy of the mesenchymal stromal cells therapy in the hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015164

Enrollment

Registered

2014-09-15

Start date

2012-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post transplantation GVHD

Interventions

intravenous administration of mesenchymal stromal cells

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who are high risk for bone marrow failure after the transplantation

Exclusion criteria

Exclusion criteria: The patients who have uncntrol infection, allergy for MSC, abnormal Cre and T-bil.

Design outcomes

Primary

Measure	Time frame
Safety of the therapy	—

Countries

Japan

Contacts

Public ContactYoshiyuki Takahashi

Nagoya University Graduate School of Medicine Department of Pediatrics

ytakaha@med.nagoya-u.ac.jp052-744-2294

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026